Methotrexate
Methotrexate - Related Videos
08:38
Genome-wide Protein-protein Interaction Screening by Protein-fragment Complementation Assay (PCA) in Living Cells
0 Views •
Cited by 27 •
2015
Proteins interact with each other and these interactions determine in a large part their functions. Protein interaction partners can be identified at high-throughput in vivo using a yeast fitness assay based on the dihydrofolate reductase protein-fragment complementation assay (DHFR-PCA).
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
0 Views •
Cited by 26 •
2013
Psoriasis is a chronic, immune-mediated inflammatory skin disease. The Goeckerman regimen, formulated for the treatment of psoriasis, consists of exposure to ultraviolet B (UVB) light and application of crude coal tar (CCT). The following protocol is for the administration of Goeckerman therapy for the treatment of moderate-to-severe psoriasis.
FAQs
After cellular uptake, methotrexate is converted to polyglutamated forms that participate in its intracellular pharmacologic action. These forms inhibit dihydrofolate reductase along with other folate-dependent enzymes, reducing the availability of tetrahydrofolate. The resulting disruption of folate metabolism limits production of thymidylate and purines, which cells require for DNA replication.
Thymidylate and purines are essential building blocks for DNA replication. Methotrexate limits their synthesis by reducing tetrahydrofolate availability, so cells have less capacity to replicate DNA. This biochemical effect helps explain its activity against rapidly dividing cells and supports its pharmacologic use in both cancer treatment and immune-mediated inflammatory conditions.
Methotrexate responses depend on more than the administered amount. Dose and treatment schedule influence exposure, while distribution into tissues and the rate of clearance affect how long pharmacologic effects persist. These variables help explain why treatment must be individualized and why pharmacokinetic considerations are central to balancing therapeutic effects with toxicity monitoring.
Methotrexate interferes with folate metabolism by inhibiting dihydrofolate reductase and other folate-dependent enzymes. Because this action reduces tetrahydrofolate availability, folic acid supplementation is an important clinical consideration during treatment. Its inclusion reflects the need to account for methotrexate’s effects on folate pathways while maintaining an appropriate therapeutic approach.
Toxicity monitoring is necessary because methotrexate effects vary with dose, schedule, tissue exposure, and clearance. Differences in these factors can change the degree and duration of folate-pathway inhibition. Monitoring therefore forms part of clinical practice, helping pharmacology-based treatment account for individual exposure while pursuing effects in cancer or inflammatory disease.
Methotrexate has applications across cancer treatment, rheumatoid arthritis, psoriasis, and other inflammatory disorders, and it can also support medical management of ectopic pregnancy. These settings differ in their therapeutic goals, but all rely on controlled effects of the drug’s folate antagonism. Dose, schedule, tissue exposure, and clearance remain important to its use across these contexts.